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TobIa 1 Contlicls of Inlmasl bOlw an Individual and soclmy
PHARMACOECONOMICS AND DECISION ANALYSIS
Ac ordlllg to Thornron nd Lilford [2): 'deCISion analy is is
a way r separare th" trcatll1en that add nel v. lue from those
that do nor, :Ifl I to COlllp re the relative valuc of bencfici;tl
tn:atl11enrs, on thc •ssumption thac it might nor be possible to
implement them all'. This is. indeed, the case for any lIew
anribionc r any new cephalosporin lIltroduced in the marke!.
Pharrnacoceonomics is a relativdy ncw discipline, which
consist, of a syscematic approach to decision analysis to
detennmc the most cost-effective thcr:Jpy among thc avnibble
aItematlves. PharnlacoCCOnonlJc reasoning starts from the
standpoint thar. III • ny rca I eCOnOlTllC SystClll, re 'ources arl'
arce in relanon to needs nd demands. This IS also tnIe fol'
healdl arc ,)"ocean, both public and private. Therefore, those
who plan, provide, receive or pay for hc.lth ervic~ mmr
rmke choices among suitable and available alternatives [3].
The chOIce are made consIdering clle 'opportllnJty cOSt',
which is the co, t of the best altemativc progrnmll1e rhal' ha, ro
bc abandoned hy comnmtl1lg the resource... in questi n to lhl'
I'rogrolt1l1l1e host'n.
Finally. the choices must b' directed r obtain thc
maximum bcnefit to so "IeI)'.
PhannacoeconolTllcs is 'the description and analy.ls of rhe
cos of drug tllCr:Jpy to healrhcare systems and society' I"j.
In hoosing the III 5t cOSt- 'ffe rive: lIIong che . vailable
[reamlen . wc should apply a rational ,Ipproach t dIe problem
of redillribution of limitecl re our l'S, ignoring thc tempcltion
imply to cut expenditure. low 'ver, the III Sf oSI-effecrive
treatJncnr for sociel), is not l1e cssarily lhc mo. t eire tiv' (clr all
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Flfl)' Yt'an a~). al the ome of lht' fjrsl cephalOlponn disc wI)'.
very iew anrihlOtic~were on rho: market and v 'ry lew alrcmativcs
wen: .w. liable 10 physici. m for rll(' Ire. tlllCIll of all inft riOll
dl..e,.'>(,'. Ph. nllacoecon Illi ~ was an unknown disciplinc. and
the ClullCl.1ftS dId nor fed it \ as a useful rool to select drugs.
Sine.. then several cephalosporin.~ and other p-Iawnll have
been dc:vdopeJ wnh progressivc wldellll1g of the ~pcctrUI11 of
.KnOIl and incrl'asmg reSIStanCe to P-l tamases. a., wdl as
improvement of the dinic.1 efficacy and of the systemic
t ler.lblhl)'. Moreover, some of the widely prescribed
ccphalosponns show Improved pharnlacokineties: long half-
hfe. oral bloavallablhry, good tISsue diStribution.
The IIlfroJucl:Jon of neW generations of ccphalosporin
mcreased their lIS'. Ho.. ever, every new ccphalosporln (in
gencral every new antibiotic) inl:fodllced In Lhe 111 rke[
involved a \Igmfiealll' illCreale of the 0 r per gr.unn1l.' of
.1I1tibioric, and ther fore ~11 III rea Ie of the cost of rreatment.
cientific ~nd technolOgical progress involves a cOSt ;ll1d it is
n >ht thaI the n13rkcr nwe this.
TIll' market 'ontributes to rhe .ro s D mesti Pro luet;
therefore, it su.stams the expendJllJrl: of the public and povate
health 'avice. as weU ,~ pharnlaccllrical rc~scar h. he market
profit is. in fact. the prin!.1ry llpptm of tl1C re car h which i.
tllC 1I1.11t1 thrml for developing lIew therapeutic drugs.
Although there IS • direct proportionaJky between wealth
and he lth expendirure of the n:mon., III the past fe\ de ade
rhe healrh expendirure of developed countries has increased
greacly. Thi.s re ult c n be explained. al le~st IfI part. by the
• pid developll1cm f ne\ and 1110te ;lIld 111000l' expcmi e
tcchnolob,jes cal able of upplYll1g rhe demo nd of health hut
al50 of inducing new. mainly irrational, needs. Thi fecd-
orw, rd loop IS more evident in the field of di. gnosric , but it
i.l alw present In the phanna C:UtlCal are, .
Therefore, It 15 urgent to keep health expendIture uncia
comrol by gWlng a value t the ~clenrifie n techn logical
cleve! pmenr .1nd by making expli it the willlnb'TlCS to pay an
increased COst for incremen of efficacy lid/or efficiency
brou~ht about by ,"novati I~, Thi goal can be reached by
dopLing sy temaric.lIy decision nalyslS methodology fJ J.
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H<:r<:. ~lIl1hlllnC U pH"C'll1- ,I luglwr prob.lhiliry of 'II Cc'"
th,1I1 don ,lI1l1hlOlIC A..1Ild II 1\ I'herd(Ht: I'rdi:rn:d hy the
I',Ull'l][ Jlld hv 1m I'hy"CI.1I1. Howl'ver. If' Wl' cOllsldcr I'h<:
"ltlnl'lll'l' III 1I11' re'l'e<:I'I\'e COSt, Jl1d rill' rdel',ll1[ dltTer<:l1<:c' of
p.lIll'lll l'lIred Wllh ,I gl\'<:11 .1I1101l1J( of 1ll()l1l", the log-I ,I
,hmc<: III thl' I' 'I'lopecuv<: Ot' ,oCI<:ry ,hollid h", anrihlOlIl: A,
wIll 'h, hl'\IlI,', ..1'SlIrl', ,I good IC'\'c·1 "f 'lIl't'<: ,
111 1I1l\ c:x.lIl1l'k rhe ,ollllKl of IlIl'l'rl"\t, h"I'\\','ell III hvidll.oI
".11'1<:111 ;111.1 St>eleN l\ l'VHIt'nL How<:vcr. thl' ,01111'1011 of
l'homlllg the 1lI0st cosr-d1"cul'e ,llremJIIV" lor the society
doc, lIot pl'l'\ll.lde ,'v,'ryhodv: 111 6et, e,1(h of us could pcrcclvc
rill' prnhklll "feqlllty of rc'" url e .00Ioc.ltIClII III ,J dllf<:rellt W.1Y·
CO'l/bcllcl;t all,d. 11'. while II hl'll" III ChOOSIIIl,\ rhe ,llr,'n1.l1ll'e
Ih,lI' 1I1,XIIlIIZl'S the h"nelJb to ,I poplllanoll wlthjll .1 1i1ll1l<:c1
bml~<:t, II delctlllllle\ allocmv\' pnonry wHhom ta!ulll-: illto
,ICCOUIll the 'p<:opk valu<:,'
Appll .IUOI1 of phantl;lCol'CnI101111n h,~ b<:cl1 Jdvocared
hy gOV<:n1lllellts ,md J(,ldel1t1c a\.l W.l)' of recollCllllli! 1I1Crt'J>1I1~
del1l.111\l' ji,r (<::o.:peI1Sil'l') mediclnc'\ Willi ,I limited .1blht)' t t1111d
th<:lr ,upply l:il. IW;l\b). inde<:d, phall11.Il'OeCOllOlIllC sllIdl<:S
;lr<: utihzed 111 111.111, COllllml'S lor pnce )IISlIfi<:aDoll. f)r 1I1dminn
III n~t1oll~1 or lo,~l t0I111Ill.1rv. t(lr C~l:lhli.,llIn).: 11t<:n,1 of
CO\'JYIII<:1lI or rl'Ullburst:lll<:1lt Jnd ~Iso for rq,'\lbtol)/ ~ppro\':ll.
COSTS AND CONSE~UENCES
Oper:lri\'dy. 'pll.lnll,lt"oecollolllIC l"l'Sl'o1rch i\knnfics, mt":l~urC\
,llld COIllP:lf<:S tilt' co~n. .lll t const'<(llellcc. of "hartll' ccullcal
pfodllct, ,IIlJ "'fVIC<:S' 1-1 I.
ECOIIOIIlIC ,m,rly'" dcals WIth both IIIp"t~ .Illd Ulltpllll>.
\(lllll't1l11e~ ",llInl co,rs ~Ild 011\ 'CJul'nces. of o1Ctl It1<:,.
Tro1ditlollJUy, there ,II'" three differcnt types of cost. ji>r a
I--'1V<:11 h('alrh progTalllllle: ,II r"l't , II1direct ;lIld illt. Ill;lhl,'. The
!iT/'a COSl' of a tn:atlllCllt COl1mt of til<.' re~ollrccs spent by tit,·
H<:alrh 'arc S)'stl'IllS III org;lIllZlll~ ,uld pn dllclIIA tilt'
tllef. P<:UtI programme ('Health arc I1lrc'ct costs'), and rhe
patient ~Ild lalluly IllpUI lilt [hc' treatlllt:1l1 ~nd thc'\ ollt-of
1'0 'kel e:o.:p"1\. t:, (' on-Ht:;Jlth Dm'ct CllstS').
Th<: ;"'/""(/ C(l't~ ,Ire the C (r of till' time Imt trulll work hy
the p. uemt .1Ilt! l)l~ t3l1l1ly b<:call'<: of l'reo1tlllCnt.
11I'(/II,~j/Jl<, co;~ :Ire the psy '11, lo~c:ll nsr" \uch ,s the
worsel1l1lA of 'Qu;lhry ,If Ltf'c' he :luse of aJvct\" 'Irut:
rc,\ctlons, or ,ul"nllg lIl\'ahdlty or bcreav"lllc'l1l.
The cOllsequellc<:s 0 drug thao1!'y lIlclud" bend;ts for both
pallellt . \Ill '0 'Iery, \ III h m:l)' bt: lIl'antltit'd III tC'l1llJ of
he.lth OlllCOlllCS alld tlu.lity of life, 111 ~ddltloll to purely
<:conolluc Illlp.I'ts,
;Jch of the f.1Ctor COll~ Illust bt: Idl'llnli<:d .111<1 '111, Ilntied III
r<:brlon r I lhe dl'Clslon problem Howevct. the chOle<: of th<:
rclt:\'allt COSt t:ll'rors, a~ well as of rhe rdev nt cOllsCqU<:IlCl'S.
depend Oil Ih\' perspc'nl\'C' of the: den"on 1Il.1kn.
Eandi st al Applying pharmacoeconomlcs 10 anllbiotlc use \)1
e IslOII ,Ilaly,,' IS usually ,t:nJ rureu Jccortlll1l'( to Ih ..
pct\pc'ctlve 'It" a I;lven deCl\IOn-llI, ka. The 1ll~1I1 d<:C1\lon-
lllakt'r\ :11'" ,1\ lollows' the: hospltalll1;lnaR 'I'. t1w IIlJnal':er of the
Nat1OIU! H<:. Ilh Clre Svsrelll (or ther tlurd party, 'u h ,IS
II1sur.lllc<:). OCIl'ty, alll!. bnally, th<: I'"u<:nt.
Thl' dln'cn'lll kCllloll-mak<:" can have conf11 IIllg IIltcrt:'< s;
"'1' 1':o.:~llll'l<:, the: C\lllt ~r bc,twcell a pn\'Jtl' hosl'llal rewMdl'd
.Kl" rdlll/.: to the: 1)I~G 'y'tdll Jlld thc Jtlon.1 Health 5"'1'\'1 e
(NH ') that pays rhe hospital and m,r.1Im th... overal burdt'n of
rh,' health care aSSlStal1ce.
THE ROLE OF PHYSICIANS, OF ANTIBIOTIC CHARACTER-
ISTICS AND OF THE HEALTH-CARE ORGANIZATION
Phy ICI~n.s h.w<: , cruCial resporuibliity 111 conrrolltl1R the cmrs
and the llU[comes of' anulloae rherap\'. III conlTolSC, llucra-
blolo!!,ICJ! ,llld phanll.l('olo~C,11 ch,lr cterunl's of :llloblOnn
IIlflucnct: thl' phy,lClans' dlt1ice , . t <:,'tlng their nsk/bl'lIehl
fali( as well ", th ...ir cost/ben ,tit ratio
The SOCIal ellvlrollll1ent J wdl;l.\ the ty!,t: of hl'3lthcJrt:
Ofj;.1ll1l,ltlOI1 allli welf:lre t.lte call also 11111ucllce both tIl<'
phY'lclalls choicc; and rht' o\tlefficac)' 01' n al1UblOOC
rh<:r:11'
Thl' use of a ncw nriblollC call U\o,lIfY the 'coSt of rlJllt: '
of.1 gIVell IIllc 0011\ dl,ease, both Il1tTOJIICll1~ ncw t: et rs or
din: 'I' costs (c.g. ,cquisitlon ,l1d ,ldllUm,traUolJ mL\, com of
,ldvcl. e dnl{.\ rca tI IlS, ct .), alld dcerea'lOg or III rCJSIlI!:
dm:ct alld/or mdlreCl co,ts (e.g, numbl't ()' hospJt:!l adnllS-
'1011.\. lCIll-'th of hospital sr,ly. tlllyS of losl work. SOCIal sccunry
P;\YIII(,II[~. etc.),
The phY~ICI~1I ho()sl'~ thc antlbi tJ , thc dme rCj:{llllen
al1d rhe rom~ of ,IdnUIll I' .Irion..15 \ ell as thc' o\' 'rall rh~ra­
P<:\ItlC strJtegy,
The ph.lnll..1Co!unenn and ph.1lln,1(o!unctlc-plumlac
dYllallll ,. of :lIlUhlOlle arc (tl1cdy eorrdat"d to the dos<:
r<:!:tllllell ,nd rhcreC. rc r [h~ dlr~cc cosr.' o( trc:ltIl1cnr
(,lCqm mon c ~t , cOS[S o( mar"oals dnd labor lor pH'p . Don
.1Il,1 . dlllllllSrt:lllOll, ct ,).
Long luif-llfe ee\'h losp rins, mch ,n ·cltn.1x nc" Uow the
USl' oflow L'rCllucnl regllllcm and r~ult III co~t-s.JVlIlg due III
redll I'J Co;[\ of Ill. ten:lls and labor lime
Moren""r. the type of dosage: hcdule dnd roUlC f
,ldllUl1I tratlon ';111 opUIIU2e the c1l11l01 dUe, . and r"duce
Ihe nsk of advem' druf: r~a nOll.'l and of <:rncrgu1g rCSI.'lI.10 c
1(,1. Thcrelor,', th,' com r. dv('n;~ dnlg rcol nons alld the em
.lmlllg from suboptimal dE "1' c, n abo bl' rdaled to the
phanll.lcoklllellC\ o( anllhiollC .
Fmall, th<: type or do~age rCglmen C~1l :llleer thl"
lI11plclllt'Ilt.11101l o( more cou-effecnve rhcrJpeutlc t:r.ltcgJcs,
sllch as rh<: oUlj'J[lent parenteral anobJotle rhenpy (OPA or
',wit h thcrapy' [7-\)j.
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he ecom nuc advam.1gcs f amlblooc oraJ cherapy Over IV
delivery 3re well known: I w,"r acqUisti n cosI of oral
fonnul:1tion , Ih.· minimal expertise required for adll1iniscra-
CIon. reduced COSl"\ tor prepar3lion and adlJlini cran n, . nd
avoided CO'I~ 0 material and of \va5cage :!.\sociau::d with
parenteral de1.Jvery f1Oj.
Moreover. oral thcrapy IS morc omionable for thc paClelll:
thc m f phleblCls. e)m:!va all n, lin,· lIlfccti II and ocher
compLicaliom of iv adnlJlmtr.lOon arc avoided; nl .Idmini -
trauon requires lC5' nursing carc, and abovc all. a]Jnws a higher
fleXibIlity nf ciJmcaJ care. Th. bst point is pamcularly reJevant
from the cconolTIJCal poine of view. be ause oral antibIOtic
thenpy F.1a1Jt;ltes earl dischaq;e from ho pltaJ and can avohl
th,' hospItalization of the Jess. cvere patient'.
The cmc ~1Vmgs of switching patients from parcnteral to
oral therapy have been eStImated in relation to the saving of
Ollcsml:t time labor 111 hospita.l II I),
Early chscharge lS a very 1J1lpOrtant means ofCOSt saving 1121.
However. c:lrly dl-scharge Il5U. lIy causC5 Incrca cd outpanent
hcaJthcaJe COSl'>. which arc charged to thc NH . Therefore••1
global 'trategy must be implemented (() solve the confll t
berween the hospital and the NHS or other third-parry p:lyer.
From an NH' perspectwe. n 111.~or cost-saving strategy u
aVOIdmg hmpital admiSSIon. ntl antibiooc therapy fosters thi~
outcome. However. PdOCOts \ ho need parenteral 3J1tibiotcs can
abo be treated at home, a cordm/t to the PAT strategy 171.
The need lor hospicilizatloll to adnunister iv antibioti
therapy depend 011 local S cia-economical 'onditiollS and
hcalthcarc org;mizal1on.
In Italy there is a WIder lise of parelllcraJ antibIOtics boch tor
outpaocnts and or 1111" oems, in compari on with other
countncs. he JitTeCl:nce is mainl due to llIore lise of rhe 1M
roule of dmimstTation. which IS • Imo I lOcally unknown 111
other countries r131. This prescription attitude is supported by
loc:l.l ocio-cultu J factors and by the phannaceutical It.jjnn
m:u-ket. Furthermore, the popularity o( 1M antibiotic admin-
Is[r.oon mcaJlS that PA IS a Viable option m ImJy.
Milny tactors vcr PA I~.<JI: It IJ1CTeascs qu.lity of lite.
reducd the n-sk 0 no oconual IIIfcctl ons, aJJO\ a grc:llcr
efficien • in h~th management and teduces the overall os
of rrcatmcl1l of infectious eli 1:'. cs. Antibl tics Ihat arc &afe and
easy co me re nc e. ary for PA. In . ddition.. u h
antibIOtic ~hould have the following characteristics: wide
spectrum of activity. covering the Likely pathogens; the
posSIbility of I or 1M admmistratlon; an adequate half-lif,o
thai aIlO\ I \ rrequlmcy reglln'IIS, good tis ue penctrati n.
high effi cy. nd g d role. bllity,
Among the, ncibloti ui ble for Or}AT, cftri,xonc IS
one o(the mo~tll ed beca,use firs wiele spectrUm and the vct)'
long half-life that allows a ingle daJJy do c.
The usc oforAT an altern tive t hospital admission i a
go d example of pnctlcaJ application of the opponunity-cost
ritt'na. In the U. A. it is cstimated that PAT lJeatmcnr c s
:Ibou[ onc-tlmd of the relative DRG V:tJue.
CONCLUSIONS
M:1I1Y difraenr tr.1lcb-ie, of anrimicrohial ost-conrailllllCIll
have bcclI proposecl and do 'ulllcnted rc 'ently: promotion of
therapcutlc cqulvalents at lower cost; lise ofsmglt' agcnt; lise of
single dose therapy: decreasing the duration f therapy: usc of
oral therapy when ti.-asiblc; lise 0 long half-lift' anribioti s:
carly elllpiri .1 rreaunenr: . \'itch therapy. nd PAT.
Pharmacoc:conomic has found its way and its role in
upporung the m;earch of OUlcomes and in fuvonng the
IIl1plc:mcutation of systcmatlc deciSion 3naly i.s to the rational
lISe of rc ources 111 nL1lIY therapeutic fields. and in pamcubr in
Ihe field of antibIOnt: therapy of infectious disease.
Our wish nd hope is thaI, in the lIext 50 years.
pharmacoeconomlc rea onillg WIU mducc a more widcsprc<ld
conscJnumes, of the need to redistrihute tlle ht-altll resour es
. Uova the world \ ith Illcreasingly 11I0re equity,
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